Scarica l'app Stockscreener
240.48
0.34%
-0.83
Dopo l'orario di chiusura:
239.13
-1.35
-0.56%
Precedente Chiudi:
$241.31
Aprire:
$240.94
Volume 24 ore:
1.03M
Relative Volume:
1.15
Capitalizzazione di mercato:
$15.61B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-13,069.57
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
-2.86%
1M Prestazione:
-6.25%
6M Prestazione:
+29.34%
1 anno Prestazione:
+89.50%
Intervallo 1D:
$239.28
$244.46
Intervallo di 1 settimana:
$236.00
$249.00
Portata 52W:
$123.88
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
240.48 | 15.66B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals CEO Renee D. Gala Reports Share Sales and Tax Withholding on September 8, 2026 - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and a 17.28% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Stock Price Forecast. Should You Buy JAZZ? - StockInvest.us
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? - Yahoo Finance
Four September conference talks will include Jazz Pharmaceuticals - Stock Titan
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? - Yahoo Finance
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth - insights.citeline.com
Jazz Pharmaceuticals PLC (JAZZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next - simplywall.st
Insider plans more Jazz (NASDAQ: JAZZ) share sales—but how big is this next trade? - stocktitan.net
JAZZ Rises on Updated OS Results From Gastric Cancer Study - Yahoo Finance
Canaccord reiterates Jazz Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Nigeria
Jazz reports Phase III trial interim results for Ziihera combination - clinicaltrialsarena.com
Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032 - TradingView
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
No-Moat Jazz's Growth Supported by Strong Clinical Data for Ziihera and Expanding Opportunity - Morningstar
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares in 2026 - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares - stocktitan.net
Jazz Pharmaceuticals (NASDAQ: JAZZ) director lines up 3,852-share sale for 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans sale after 18,000 shares sold - Stock Titan
Positive Phase 3 Survival Results in HER2+ Advanced GEA – Jazz Pharmaceuticals - Oncodaily
Cancer drug decision could swing Jazz Pharmaceuticals' beatBizwomen - The Business Journals
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment - GuruFocus
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A 17% Upside Potential Lights Up Investor Interest - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera - simplywall.st
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - Finansavisen
Jazz Pharmaceuticals prices $1.1B exchangeable notes offering By Investing.com - Investing.com Nigeria
JAZZ PHARMACEUTICALS PLC : DEUTSCHE BANK RAISES TARGET PRICE TO $300 FROM $287 - webull.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032 - marketscreener.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering - Investing.com
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):